Curis to Release Fourth Quarter and Year End 2012 Financial Results and Hold
Conference Call on February 20, 2013
LEXINGTON, Mass., Feb. 13, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS),
a drug development company seeking to develop proprietary targeted medicines
for cancer treatment, today announced that the Company will release its fourth
quarter and year end 2012 financial results on Wednesday, February 20, 2013,
before the market opens. The Company's management will also hold a conference
call on the same day at 9:00 A.M. Eastern time to provide an overview of its
proprietary research and development programs, including CUDC-427, CUDC-907
and CUDC-101 as well as its partnered programs, including Erivedge®
(vismodegib) and Debio 0932.The Company's management will also review its
financial results as of and for the fourth quarter and year ended December 31,
2012. Daniel Passeri, President and Chief Executive Officer of Curis, will
host the call.
To access the live conference call, please dial (877) 868-1829 from the United
States or (253) 237-1135 from other locations, shortly before 9:00 A.M.
Eastern time.The conference ID number is 98576283.The conference call can
also be accessed on the Curis website at www.curis.com in the Investors
section. Replay will be available approximately two hours after the completion
of the call and through 5:00 P.M. Eastern time, Tuesday, February 26, 2013.To
access the replay, please call (855) 859-2056 from the United States or (404)
537-3406 from other locations and reference the conference ID number 98576283.
About Curis, Inc.
Curis is a drug development company seeking to develop and commercialize next
generation targeted drug candidates for cancer treatment. Erivedge® is the
first and only FDA-approved medicine for the treatment of advanced basal cell
carcinoma and is being commercialized and developed by Roche and Genentech, a
member of the Roche Group, under a collaboration agreement between Curis and
Genentech. Curis is also leveraging its experience in targeting signaling
pathways to develop proprietary targeted cancer programs, including CUDC-427,
a small molecule IAP inhibitor, CUDC-907, a dual PI3K and HDAC inhibitor, and
CUDC-101, an EGFR, Her2 and HDAC inhibitor. For more information, visit Curis'
website at www.curis.com.
The Curis, Inc. logo is available at
CONTACT: Michael P. Gray
CFO & COO
Curis, Inc. Logo
Press spacebar to pause and continue. Press esc to stop.